Sirolimus, a New, Potent Immunosuppressive Agent
Authors:
- Scott A. GruberSGScott A. Gruber
- Fariba BehbodFBFariba Behbod
- Barry D. KahanBKBarry D. Kahan
- 12 November 1997
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 17 (6) , 1148-1156
Abstract
Sirolimus (SRL), a potent immunosuppressant, is currently being investigated in phase III trials for prophylaxis of renal transplant rejection. The mechanism of action of SRL is a blockade of the response of T and B cells to cytokines, thereby preventing cell cycle progression in G1 and consequently cell proliferation. There seems to be a good correlation between SRL concentrations, estimated as exposure by the area under the concentration versus time curve, and trough whole blood concentration, so that therapeutic monitoring may be done by trough levels only. Because of the low frequency of allograft rejection, there has been no documented correlation between trough concentrations and efficacy. Trough SRL concentrations of 15 ng/ml or higher seem to be associated with an increased frequency of adverse effects. Drug‐associated toxicities include thrombocytopenia, leukopenia, and increases in cholesterol and triglyceride levels. The drug has synergy with cyclosporine (CsA) in vitro as well as in animal and clinical studies. In phase II trials the combination of SRL‐CsA therapy reduced the frequency of acute rejection episodes, permit withdrawal of concomitant corticosteroid therapy, and allowed reduction of CsA dosages in nonblack patients.Keywords
This publication has 58 references indexed in Scilit:
- Potential Applications of Therapeutic Drug Monitoring of Sirolimus Immunosuppression in Clinical Renal TransplantationTherapeutic Drug Monitoring, 1995
- A Putative Sirolimus (Rapamycin) Effector ProteinBiochemical and Biophysical Research Communications, 1994
- Blood Distribution Of RapamycinTransplantation, 1993
- Rapamycin Inhibits p34cdc2 Expression and Arrests T Lymphocyte Proliferation at the G1/S TransitionAnnals of the New York Academy of Sciences, 1993
- Measurement of Rapamycin in Whole Blood Using Reverse-Phase High-Performance Liquid ChromatographyTherapeutic Drug Monitoring, 1992
- A rapamycin-selective 25-kDa immunophilinBiochemistry, 1992
- The mechanism of action of cyclosporin A and FK506Immunology Today, 1992
- Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexesCell, 1991
- TOXICITY OF RAPAMYCIN—A COMPARATIVE AND COMBINATION STUDY WITH CYCLOSPORINE AT IMMUNOTHERAPEUTIC DOSAGE IN THE RATTransplantation, 1991
- Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.Proceedings of the National Academy of Sciences, 1990